Table 2 Treatment
From: Sacral insufficiency fractures after high-dose carbon-ion based radiotherapy of sacral chordomas
Characteristics | Value | Percent | |
|---|---|---|---|
Resection status (n) | |||
Biopsy | 24 | 42.9 | |
R2 | 19 | 33.9 | |
R0/1 | 13 | 23.2 | |
Treatment (n) | |||
Primary | 42 | 75.0 | |
S.p. biopsy | 21 | 50.0 | |
S.p. R0/1 resection | 10 | 23.8 | |
S.p. R2 resection | 11 | 26.2 | |
Recurrent | 14 | 25.0 | |
Additional biopsy | 1 | 7.1 | |
Additional R0/1 resection | 4 | 28.6 | |
Additional R2 resection | 9 | 64.3 | |
Radiation dose | ED 2 Gy | ||
Carbon ion only: | (α/β = 2) | ||
60 Gy/3 Gy (RBE) | 75.0 Gy | 16 | 28.6 |
63 Gy/3 Gy (RBE) | 78.8 Gy | 2 | 3.6 |
66 Gy/3 Gy (RBE) | 82.5 Gy | 15 | 26.8 |
IMRT + carbon ion boost | |||
50 Gy/2 Gy + 15 Gy/3 Gy (RBE) | 68.8 Gy | 1 | 1.8 |
50 Gy/2 Gy + 18 Gy/3 Gy (RBE) | 74.5 Gy | 1 | 1.8 |
50 Gy/2 Gy + 24 Gy/3 Gy (RBE) | 80.0 Gy | 21 | 37.5 |
GTV (n = 43; ml) | |||
Median | 244 | ||
Range | 5–1188 | ||
CTV1 (n = 43; ml) | |||
Median | 522 | ||
Range | 64–1743 | ||
CTV2 (n = 56; ml) | |||
Median | 937.5 | ||
Range | 60–2404 | ||
PTV1 (n = 43; ml) | |||
Median | 614 | ||
Range | 0–2325 | ||
PTV2 (n = 56; ml) | |||
Median | 1067 | ||
Range | 84–3099 | ||